Adverse karyotype amplifies risk in secondary acute myeloid leukemia (AML) and AML with myelodysplasia-related changes.

Matsukawa T, Yoshida S, Onozawa M, Fujii F, Nagai J, Takahashi T, Ota S, Hashiguchi J, Mori A, Miyagishima T, Ibata M, Kakinoki Y, Oyake T, Yamamoto S, Hayashi T, Wakasa K, Saga T, Igarashi T, Iyama S, Tsutsumi Y, Fujimoto K, Adachi M, Yoshida M, Hashimoto D, Teshima T

Open source

DOI: 10.1080/16078454.2026.2628479
Published: 2026 Dec
Container: Hematology (Amsterdam, Netherlands)
Publisher: Taylor & Francis
Open access: no

Credibility signals

uncertain Score 59/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
supportingPublication license: A publication license was supplied: https://creativecommons.org/licenses/by/4.0/legalcode. Presence improves reuse transparency, not research validity. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1080/16078454.2026.2628479,
  title = {Adverse karyotype amplifies risk in secondary acute myeloid leukemia (AML) and AML with myelodysplasia-related changes.},
  author = {Matsukawa T and Yoshida S and Onozawa M and Fujii F and Nagai J and Takahashi T and Ota S and Hashiguchi J and Mori A and Miyagishima T and Ibata M and Kakinoki Y and Oyake T and Yamamoto S and Hayashi T and Wakasa K and Saga T and Igarashi T and Iyama S and Tsutsumi Y and Fujimoto K and Adachi M and Yoshida M and Hashimoto D and Teshima T},
  year = {2026},
  journal = {Hematology (Amsterdam, Netherlands)},
  doi = {10.1080/16078454.2026.2628479},
  url = {https://doi.org/10.1080/16078454.2026.2628479}
}

RIS

TY  - JOUR
TI  - Adverse karyotype amplifies risk in secondary acute myeloid leukemia (AML) and AML with myelodysplasia-related changes.
AU  - Matsukawa T
AU  - Yoshida S
AU  - Onozawa M
AU  - Fujii F
AU  - Nagai J
AU  - Takahashi T
AU  - Ota S
AU  - Hashiguchi J
AU  - Mori A
AU  - Miyagishima T
AU  - Ibata M
AU  - Kakinoki Y
AU  - Oyake T
AU  - Yamamoto S
AU  - Hayashi T
AU  - Wakasa K
AU  - Saga T
AU  - Igarashi T
AU  - Iyama S
AU  - Tsutsumi Y
AU  - Fujimoto K
AU  - Adachi M
AU  - Yoshida M
AU  - Hashimoto D
AU  - Teshima T
PY  - 2026
JO  - Hematology (Amsterdam, Netherlands)
DO  - 10.1080/16078454.2026.2628479
UR  - https://doi.org/10.1080/16078454.2026.2628479
ER  -

APA

T, M., S, Y., M, O., F, F., J, N., T, T., S, O., J, H., A, M., T, M., M, I., Y, K., T, O., S, Y., T, H., K, W., T, S., T, I., S, I., Y, T., K, F., M, A., M, Y., D, H., & T, T. (2026). Adverse karyotype amplifies risk in secondary acute myeloid leukemia (AML) and AML with myelodysplasia-related changes.. Hematology (Amsterdam, Netherlands). https://doi.org/10.1080/16078454.2026.2628479

Source records

pubmed · retrieved 2026-09-25T23:57:42.747Z
europe-pmc · retrieved 2026-09-25T23:57:42.757Z
datacite · retrieved 2026-09-25T23:57:42.745Z
datacite · retrieved 2026-09-25T23:57:42.745Z
doaj · retrieved 2026-09-25T23:57:42.768Z